Antibodies News and Research

RSS

Majority of people infected with mild-to-moderate COVID 19 mount robust antibody response

The vast majority of individuals infected with mild-to-moderate COVID 19 mount a robust antibody response that is relatively stable for at least five months, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 28, in the journal Science.

29 Oct 2020

Researchers estimate prevalence of SARS-CoV-2 antibodies among adults in orange county

Testing a representative sample of Orange County residents for a wide range of coronavirus antibodies, University of California, Irvine researchers found that 11.5 percent of them have antibodies for COVID-19, in contrast to previous estimates of less than 2 percent.

29 Oct 2020

Mouth may be primary route of SARS-CoV-2 infection and transmission

A new study published on the preprint server medRxiv in October 2020 shows that the virus also multiplies robustly in the oral cavity, indicating that saliva plays a role in viral transmission.

29 Oct 2020

REACT study shows 26% decline in SARS CoV-2 seroprevalence over 2-3 months

Their study titled, "Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults," was released online as a pre-print on the medRxiv* server. This large study was funded by the Department of Health and Social Care in England.

28 Oct 2020

Deep learning models help hunt for COVID-19 drugs

Michigan State University Foundation Professor Guowei Wei wasn't preparing machine learning techniques for a global health crisis. Still, when one broke out, he and his team were ready to help.

28 Oct 2020

Cost of Covid-19 tests plays key role in people’s willingness to undergo testing

Where and how long can schools remain open in times of the Corona pandemic? How safe are public transport means? Which rules must be observed when organizing events? To answer these questions, systematic tests for Corona infections and antibodies are of decisive importance.

28 Oct 2020

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced the appointment of Stewart Kay as Chief Business Officer.

28 Oct 2020

Scientists compare ACE2 interaction with SARS-CoV-2 across species

Like other pathogenic coronaviruses, SARS-CoV-2 crossed the species barrier to cause human disease. This fact motivated the current study, published on the preprint server bioRxiv* in October 2020, which explores the way coronaviruses engage their host cell receptors in a range of animals.

28 Oct 2020

Researchers demonstrate potent antibody that fights against coronavirus

Scientists at Fred Hutchinson Cancer Research Center in Seattle have shown that a potent antibody from a COVID-19 survivor interferes with a key feature on the surface of the coronavirus's distinctive spikes and induces critical pieces of those spikes to break off in the process.

28 Oct 2020

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Myeloid cells can suppress immune response, promote brain metastasis

Scientists have long believed that the brain protects itself from an aggressive immune response to keep down inflammation. However, that evolutionary control may work against it when a cancer cell attempts to spread to the brain, researchers at the University of Notre Dame have discovered.

27 Oct 2020

Research on autophagy and coronavirus, implicates ULK1

Researchers from the University of British Columbia have discovered that the betacoronavirus-encoded papain-like protease disrupts autophagy, partly by targeting ULK1. Their work is reported on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Study: SARS-CoV-2 virus adopts new strategy to ensure its replication, spread

Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.

27 Oct 2020

Lung biomarkers may predict severe COVID-19

Two University of New Mexico researchers postulate certain specific biomarkers' relevance in predicting the potential for progression to severe COVID-19 in a paper published on the preprint server bioRxiv*

27 Oct 2020

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

New peptide derivatives that target the SARS-CoV-2 spike protein

In a new study published in the journal Cellular and Molecular Bioengineering, researchers report peptide derivatives, or peptidomimetics, based on the circle residues involved in the interaction of the spike protein and ACE2.

26 Oct 2020

Small molecules block SARS-CoV-2 spike-ACE2 attachment

The search includes immunological agents, enzyme inhibitors, and soluble competitive inhibitors. Now, a new study published on the preprint server bioRxiv in October 2020 provides preliminary evidence that small molecules can inhibit viral entry by inhibiting spike-ACE2 attachment.

26 Oct 2020

Population-based COVID-19 prevalence surveys in Europe and Americas show risk of bias

A team of researchers from the Federal University of Health Sciences of Porto Alegre and the Federal University of Rio Grande do Sul performed a systematic review to assess these population-based COVID-19 prevalence surveys' reliability and biases qualitatively. Their study is published on the preprint server medRxiv.

26 Oct 2020

NRP-1 receptor potentiates SARS-CoV-2 infectivity

The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.

26 Oct 2020

Startling high SARS-CoV-2 seroprevalence in Veracruz, Mexico

A surprising new study published on the preprint server medRxiv in October 2020 reports a very high seroprevalence of IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the city of Vera Cruz, Mexico. They are among the highest to be reported anywhere in the world.

25 Oct 2020